中华实验和临床病毒学杂志
中華實驗和臨床病毒學雜誌
중화실험화림상병독학잡지
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL VIROLOGY
2010年
4期
286-288
,共3页
姜秋泉%梁伟峰%张素英%曾艳梅%孟亚妮%张永乐%娄国强
薑鞦泉%樑偉峰%張素英%曾豔梅%孟亞妮%張永樂%婁國彊
강추천%량위봉%장소영%증염매%맹아니%장영악%루국강
肝炎病毒,乙型%替比夫定%疾病传播,垂直
肝炎病毒,乙型%替比伕定%疾病傳播,垂直
간염병독,을형%체비부정%질병전파,수직
Hepatitis B virus%Telbivudine%Disease transmission,vertical
目的 探讨替比夫定阻断HBV母婴垂直传播的疗效.方法 收集2007年11月至2009年6月在杭州市第六人民医院就诊的64例孕妇,将其分为对照组(36例)和治疗组(28例),2组孕妇在妊娠第28、32和36周均肌注HBIG 200IU各1次,治疗组孕妇在孕28周时同时口服替比夫定,600 mg/d,观察2组新生儿HBV DNA载量和HB8Ag水平.结果 对照组所生新生儿HBsAg阳性率为30.56%(11/36),治疗组所生新生儿HBsAg阳性率为7.14%(2/28),2组相比差异有统计学意义(χ2=3.985,P=0.046),对照组所生新生儿HBV DNA阳性率为16.67%(6/36),治疗组所生新生儿HBV DNA阳性率为0,2组比较差异具有统计学意义(P<0.05).所有孕妇及新生儿在治疗期间未出现不良反应.结论 替比夫定在一定程度上可以降低HBV母婴垂直传播的风险.
目的 探討替比伕定阻斷HBV母嬰垂直傳播的療效.方法 收集2007年11月至2009年6月在杭州市第六人民醫院就診的64例孕婦,將其分為對照組(36例)和治療組(28例),2組孕婦在妊娠第28、32和36週均肌註HBIG 200IU各1次,治療組孕婦在孕28週時同時口服替比伕定,600 mg/d,觀察2組新生兒HBV DNA載量和HB8Ag水平.結果 對照組所生新生兒HBsAg暘性率為30.56%(11/36),治療組所生新生兒HBsAg暘性率為7.14%(2/28),2組相比差異有統計學意義(χ2=3.985,P=0.046),對照組所生新生兒HBV DNA暘性率為16.67%(6/36),治療組所生新生兒HBV DNA暘性率為0,2組比較差異具有統計學意義(P<0.05).所有孕婦及新生兒在治療期間未齣現不良反應.結論 替比伕定在一定程度上可以降低HBV母嬰垂直傳播的風險.
목적 탐토체비부정조단HBV모영수직전파적료효.방법 수집2007년11월지2009년6월재항주시제륙인민의원취진적64례잉부,장기분위대조조(36례)화치료조(28례),2조잉부재임신제28、32화36주균기주HBIG 200IU각1차,치료조잉부재잉28주시동시구복체비부정,600 mg/d,관찰2조신생인HBV DNA재량화HB8Ag수평.결과 대조조소생신생인HBsAg양성솔위30.56%(11/36),치료조소생신생인HBsAg양성솔위7.14%(2/28),2조상비차이유통계학의의(χ2=3.985,P=0.046),대조조소생신생인HBV DNA양성솔위16.67%(6/36),치료조소생신생인HBV DNA양성솔위0,2조비교차이구유통계학의의(P<0.05).소유잉부급신생인재치료기간미출현불량반응.결론 체비부정재일정정도상가이강저HBV모영수직전파적풍험.
Objective To investigate the efficacy of telbivudine blocking the spread of hepatitis B virus in intrauterine. Methods Collecting 64 cases of pregnant women who receive treatment in Hangzhou Sixth People's hospital between November 2007-June 2009,which are divided into control group (36 cases)and treatment group (28 eases). Two groups of pregnant women intramuscular HBIG 200IU each one times during pregnancy 28, 32 and 36 weeks. Pregnant women of treatment simultaneously oral telbivudine tabels,600 mg/d. To observe the HBV DNA load and HBsAg levels in newborns of two groups. Results HBsAgpositive rate is 30.56% (11/36) in newborns of the treatment group, which is 7. 14% (2/28) in control group. The difference is statistically significant between two groups ( χ2 = 3. 985, P = 0. 046 ). HBV DNA positive rate is 1 16.67% (6/36) in newborns of control group, which is 0 in treatment group. The difference is statistically significant between two groups ( P < 0.05 ). All pregnant women and newborns do not appear adverse reactions during the treatment. Conclusion HBV blocking rate of treatment group is significantly higher than control group. The results suggest that telbivudine can reduce the risk of HBV vertical transmission to a certain extent.